FDA grants Emergency Use Authorisation (EUA) to combination of baricitinib and remdesivir in hospitalized COVID-19 patients

The EUA, which is for use in patients aged ≤2 years requiring supplemental oxygen, invasive mechanical ventilation or ECMO, is based on data from the ACTT-2 study showing the combination improved median time to recovery by 1 day versus remdesivir alone.

Source:

Biospace Inc.